Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple negative breast and ovarian carcinomas

Triple negative breast (TNBC) and ovarian carcinomas (OvCas) with BRCA1 promoter methylation (BRCA1meth) respond more poorly to alkylating agents compared to those bearing mutations in BRCA1 and BRCA2 (BRCAmut). This is a conundrum given the biologically equivalent homologous recombination deficienc...

Descripción completa

Detalles Bibliográficos
Autores principales: Menghi, Francesca, Banda, Kalyan, Kumar, Pooja, Straub, Robert, Dobrolecki, Lacey, Rodriguez, Isabel V., Yost, Susan E., Chandok, Harshpreet, Radke, Marc R., Somlo, George, Yuan, Yuan, Lewis, Michael T., Swisher, Elizabeth M., Liu, Edison T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585706/
https://www.ncbi.nlm.nih.gov/pubmed/35857626
http://dx.doi.org/10.1126/scitranslmed.abn1926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585706/
https://www.ncbi.nlm.nih.gov/pubmed/35857626
http://dx.doi.org/10.1126/scitranslmed.abn1926

Ejemplares similares